Rocket Pharmaceuticals Inc. Watch

from S-3ASR 41 pages Rocket Pharmaceuticals, Inc., Issuer and [Trustee], Trustee Indenture Dated as of [●], 202[●] Subordinated Debt Securities

from S-3ASR 39 pages Rocket Pharmaceuticals, Inc., Issuer and [Trustee], Trustee Indenture Dated as of [●], 202[●] Senior Debt Securities

from 8-K 10 pages Rocket Pharmaceuticals, Inc. Pre-Funded Warrant to Purchase Common Stock

from 8-A12B 24 pages Assignment, Assumption and Amended & Restated Warrant Agreement

from S-3 41 pages Rocket Pharmaceuticals, Inc., Issuer and [Trustee], Trustee Indenture Dated as of [●], 202[●] Subordinated Debt Securities

from S-3 39 pages Rocket Pharmaceuticals, Inc., Issuer and [Trustee], Trustee Indenture Dated as of [●], 202[●] Senior Debt Securities

from 10-K 3 pages Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as Amended Description of Capital Stock

from 8-K 5 pages Supplemental Indenture to the Second Supplemental Indenture

from 8-K 83 pages Rocket Pharmaceuticals, Inc. and Wilmington Trust, National Association, as Trustee Second Supplemental Indenture Dated as of February 20, 2020 to Indenture for Senior Debt Securities Dated as of August 5, 2016 6.25% Convertible Senior Notes Due 2022

from 8-K 4 pages Amendment to First Supplemental Indenture

from 8-K 2 pages The Securities Represented by This Certificate and the Sale, Pledge, Hypothecation, or Transfer of the Securities Represented Hereby Is Subject To, and in Certain Cases Prohibited By, the Terms and Conditions of a Certain Stockholders’ Agreement by and Among the Stockholder, the Corporation and Certain Holders of Stock of the Corporation, as May Be Amended From Time to Time. Copies of Such Agreement May Be Obtained Upon Written Request to the Secretary of the Corporation. by Accepting Any Interest in Such Securities the Person Accepting Such Interest Shall Be Deemed to Agree to and Shall Become Bound by All the Provisions of That Stockholders’ Agreement, Including Certain Restrictions on Transfer and Ownership Set Forth Therein

from 8-K 90 pages Inotek Pharmaceuticals Corporation and Wilmington Trust, National Association, as Trustee First Supplemental Indenture Dated as of August 5, 2016 to Indenture for Senior Debt Securities Dated as of August 5, 2016 5.75% Convertible Senior Notes Due 2021

from 8-K 52 pages Inotek Pharmaceuticals Corporation, Issuer and Wilmington Trust, National Association, Trustee Indenture Dated as of August 5, 2016 Senior Debt Securities

from S-3 38 pages Inotek Pharmaceuticals Corporation Issuer and [Trustee], Trustee Indenture Dated as of [•], 201[•] Subordinated Debt Securities

from S-3 38 pages Inotek Pharmaceuticals Corporation Issuer and [Trustee], Trustee Indenture Dated as of [•], 201[•] Senior Debt Securities

from 10-K 2 pages Additional Abbreviations May Also Be Used Though Not in the Above List. for Value Received, Hereby Sell, Assign and Transfer Unto Please Insert Social Security or Other Identifying Number of Assignee

from 8-K 112 pages Inotek Pharmaceuticals Corporation and Wilmington Trust, National Association, as Trustee Indenture Dated as of February 23, 2015 5.0% Convertible Senior Notes Due 2020

from S-1/A 109 pages Inotek Pharmaceuticals Corporation and Wilmington Trust, National Association, as Trustee Indenture Dated as of February [ ], 2015 [ . ]% Convertible Senior Notes Due 2020

from S-1/A 109 pages Inotek Pharmaceuticals Corporation and Wilmington Trust, National Association, as Trustee Indenture Dated as of February [ ], 2015 [ . ]% Convertible Senior Notes Due 2020

from S-1/A 109 pages Inotek Pharmaceuticals Corporation and Wilmington Trust, National Association, as Trustee Indenture Dated as of December [ ], 2014 [ . ]% Convertible Senior Notes Due 2019